Evenity (Romosozumab) Cost in Colorado 2026: Pricing, Insurance, and Savings

What Does Evenity (Romosozumab) Actually Cost in Colorado?

The wholesale acquisition cost (WAC) for Evenity in 2026 is $1,825 per monthly dose across Colorado retail and specialty pharmacies. That figure has remained stable since Amgen and UCB set the launch price in 2019 1. A complete 12-month treatment course runs approximately $21,900 before insurance, placing Evenity among the most expensive osteoporosis therapies on the market.

Cash-pay prices at Colorado pharmacies rarely deviate from the $1,825 WAC. Unlike small-molecule drugs where generic competition drives retail variation, romosozumab is a biologic with no biosimilar competitor as of mid-2026. Specialty pharmacies in Denver, Colorado Springs, and Fort Collins all price within a few dollars of each other because they source from the same Amgen distribution channel.

The per-dose cost breaks down to two prefilled syringes of 105 mg each, administered together as a single 210 mg subcutaneous injection. You cannot split the dose across visits or reduce the monthly frequency. The FDA label specifies exactly 12 monthly doses, after which patients must transition to an antiresorptive agent such as denosumab or a bisphosphonate to maintain bone density gains 1. Stopping without a follow-on therapy leads to rapid bone density loss, which means the total cost of an Evenity-based regimen extends beyond the $21,900 initial course.

How Evenity Compares to Other Osteoporosis Drug Costs

Evenity sits at the high end of the osteoporosis cost spectrum, but context matters. Generic alendronate costs $10 to $30 per month. Denosumab (Prolia) runs approximately $1,600 to $1,800 per six-month injection. Teriparatide (Forteo) costs roughly $3,500 per month, while abaloparatide (Tymlos) lands around $2,900 per month 2.

What distinguishes Evenity's cost profile is its fixed duration. Forteo and Tymlos each require 18 to 24 months of therapy; Evenity requires 12. The total treatment expenditure for a full Evenity course ($21,900) is comparable to or less than a full Forteo course ($63,000 to $84,000 over 18 to 24 months) before insurance adjustments.

The ARCH trial (N=4,093) demonstrated that romosozumab followed by alendronate reduced new vertebral fractures by 48% compared to alendronate alone at 24 months 2. The 2020 AACE/ACE Clinical Practice Guidelines state: "Romosozumab is recommended as initial therapy for patients at very high fracture risk, including those with recent osteoporotic fracture, a T-score of <-3.0, or high FRAX probability" 3. That recommendation positions Evenity not as a first-line drug for all osteoporosis patients but as a targeted therapy for those most likely to fracture.

Does Colorado Medicaid Cover Evenity?

No. As of 2026, Colorado's Medicaid program (Health First Colorado) does not include Evenity on its preferred drug list for osteoporosis treatment. The formulary excludes most anabolic bone agents in favor of generic bisphosphonates and denosumab as cost-containment measures.

This is a significant barrier for the roughly 1.6 million Coloradans enrolled in Medicaid. A patient who meets clinical criteria for very-high-risk osteoporosis and whose physician recommends romosozumab will need to pursue one of two paths: file an exception request through the prior authorization process (sometimes called a "non-preferred drug request") or explore commercial coverage alternatives.

Exception requests require documentation of bisphosphonate failure or intolerance, a recent fragility fracture, or a DXA T-score of <-3.0. Even with strong clinical justification, approval rates for Medicaid exception requests for high-cost biologics in Colorado remain low. Patients denied coverage can appeal through the state fair hearing process, but the timeline (60 to 90 days) often exceeds what is clinically acceptable for someone at imminent fracture risk.

The Endocrine Society's 2020 Clinical Practice Guideline on pharmacological management of osteoporosis notes: "For patients at very high risk of fracture, treatment with an osteoanabolic agent for the approved duration followed by an antiresorptive is strongly recommended" 4. This recommendation creates tension with payer formularies that restrict anabolic agents.

Which Commercial Insurance Plans Cover Evenity in Colorado?

Most major commercial insurers operating in Colorado will cover Evenity, but only after prior authorization and, in most cases, step therapy. Step therapy means the insurer requires documented failure of or contraindication to a first-line bisphosphonate before approving romosozumab.

Plans from Anthem Blue Cross Blue Shield, UnitedHealthcare, Cigna, Aetna, and Kaiser Permanente Colorado all maintain specialty pharmacy coverage for Evenity. The typical approval pathway looks like this: the prescribing physician submits a prior authorization form documenting the patient's DXA results (T-score <-2.5 or lower), fracture history, and prior treatment attempts. Turnaround is usually 5 to 15 business days.

Copay obligations vary widely by plan design. Under a standard commercial plan with specialty drug tier coverage, the patient copay for Evenity can range from $50 to $500 per month. High-deductible health plans (HDHPs) may require the patient to pay the full $1,825 until the deductible is met. This is where the manufacturer savings card becomes important.

Medicare Part B covers Evenity as a physician-administered injectable for eligible patients. Because Evenity is given by subcutaneous injection in a clinical setting, it falls under Part B's "incident to" billing rather than Part D pharmacy coverage. The standard Part B cost-sharing is 20% after the deductible, which works out to roughly $365 per injection 5. Medicare Supplement (Medigap) plans may cover some or all of that 20%.

How the Amgen/UCB Evenity Savings Card Works in Colorado

Amgen and UCB jointly offer the Evenity Together patient support program, which includes a copay savings card for commercially insured patients. The card can reduce out-of-pocket costs to $0 per month for eligible patients, with a maximum annual benefit that typically covers the full 12-month course.

Eligibility requirements are straightforward. The patient must have commercial (private) insurance that covers Evenity. The card does not apply to government-funded insurance programs, including Medicare, Medicaid, Tricare, and VA benefits. Colorado residents with employer-sponsored or individual marketplace plans qualify as long as their insurer has approved the prescription.

To enroll, patients call the Evenity Together program or visit the program website. A case manager verifies insurance coverage, helps coordinate prior authorization if needed, and activates the savings card. The card is applied at the specialty pharmacy or physician's office at the point of dispensing.

For commercially insured Colorado patients, this program is the single most effective cost-reduction tool. A patient facing a $300 monthly copay under their plan's specialty tier would pay $0 with the savings card active. Over 12 months, that represents $3,600 in savings. Patients should enroll before the first dose to avoid paying out of pocket while waiting for card activation.

Can You Get Evenity Via Telehealth in Colorado?

Yes. Colorado state law permits telehealth prescribing of Evenity. A physician can evaluate a patient remotely, review DXA scan results and fracture history, and write a prescription for romosozumab without an in-person visit. The Colorado Medical Board has maintained expanded telehealth provisions since the pandemic-era regulatory changes became permanent in 2021.

There is a practical limitation, though. Evenity must be administered as a subcutaneous injection by a healthcare provider (or by a trained patient in some cases). The medication itself ships through specialty pharmacy. So while the prescribing and follow-up appointments can happen via telehealth, the patient still needs access to an injection site, whether that is a local physician's office, an infusion center, or home health nursing.

For patients in rural Colorado communities like Durango, Alamosa, or Craig, where endocrinologists and rheumatologists are scarce, telehealth removes the consultation barrier. A Denver-based or Boulder-based specialist can prescribe and manage the Evenity course remotely while a local clinic or home health nurse handles the monthly injections 6.

Is Compounded Romosozumab Available in Colorado?

No, not in any meaningful clinical sense. Romosozumab is a humanized monoclonal antibody produced through recombinant DNA technology in Chinese hamster ovary (CHO) cell culture. This class of biologic cannot be replicated by a 503A or 503B compounding pharmacy.

Compounding pharmacies work with small molecules, peptides, and hormones. They do not have the bioreactor systems, purification infrastructure, or quality-control assays required to manufacture monoclonal antibodies. The suggestion that compounded romosozumab exists at any price point is misleading. The FDA's guidance on biological products and compounding, issued under Section 503A of the FD&C Act, explicitly excludes complex biologics from the scope of pharmacy compounding 1.

Colorado patients who encounter offers for "compounded romosozumab" should treat them with extreme skepticism. Any such product would not contain the actual antibody and would carry no clinical benefit. The only legitimate source of romosozumab is Amgen's branded Evenity product.

Clinical Evidence Behind the Cost

The price of Evenity reflects the strength of its fracture-reduction data, which is among the most compelling in the osteoporosis field.

The FRAME trial (N=7,180) randomized postmenopausal women with osteoporosis to romosozumab 210 mg or placebo monthly for 12 months, followed by denosumab in both groups. At 12 months, romosozumab reduced new vertebral fractures by 73% compared to placebo (0.5% vs. 1.8%, P<0.001). At 24 months (after both groups received denosumab), the romosozumab-first group still showed a 75% reduction in vertebral fractures 5.

The ARCH trial (N=4,093) compared romosozumab for 12 months followed by alendronate versus alendronate alone in postmenopausal women with osteoporosis and a prior fracture. At 24 months, the romosozumab-to-alendronate sequence reduced new vertebral fractures by 48% and clinical fractures by 27% compared to alendronate alone 2. The ARCH trial also revealed a cardiovascular safety signal: adjudicated major adverse cardiac events (MACE) occurred in 2.5% of romosozumab patients versus 1.9% of alendronate patients during the 12-month romosozumab treatment period.

That cardiovascular signal led the FDA to add a boxed warning to the Evenity label, contraindicating the drug in patients who have had a myocardial infarction or stroke within the preceding year 1. Dr. Felicia Cosman, lead author on the FRAME trial, noted in a 2019 commentary: "The cardiovascular signal in ARCH requires careful patient selection, but it should not prevent appropriate use in patients who are at very high skeletal risk and low cardiovascular risk" 7.

For Colorado patients and their physicians, the boxed warning adds a layer of clinical decision-making to the cost conversation. A patient with a recent MI or stroke is excluded from Evenity regardless of cost or coverage status.

How to Reduce Your Evenity Cost in Colorado

The practical path to affordable Evenity access in Colorado follows a specific sequence.

Step 1: Confirm clinical eligibility. Evenity is FDA-approved for postmenopausal women at high risk for fracture. Off-label use in men or premenopausal women requires additional justification and may face payer resistance.

Step 2: Obtain prior authorization. Your prescribing physician should submit the prior authorization with DXA results, fracture history, and documentation of prior bisphosphonate use (or documented intolerance/contraindication). Include the cardiovascular risk assessment confirming no recent MI or stroke 1.

Step 3: Enroll in Evenity Together. Before the first injection, call the Amgen/UCB support program. If you have commercial insurance, activate the copay savings card. If you are on Medicare, ask about the patient assistance program for help with the 20% coinsurance.

Step 4: Choose your administration site. Evenity is most often administered in a physician's office, but specialty pharmacies like Optum, Accredo, and AllianceRx Walgreens in Colorado can ship directly to a clinic. Some plans allow home health nursing administration 8.

Step 5: Plan the transition therapy. Before dose 12, discuss with your physician which antiresorptive you will start next. Denosumab and zoledronic acid are the two most common follow-on agents. The AACE guideline recommends that "transition to antiresorptive therapy should begin immediately upon completion of the osteoanabolic course to consolidate bone density gains" 3. Do not leave a gap between Evenity and the next medication.

What to Know About Medicare Part B Coverage in Colorado

Medicare Part B covers Evenity under its injectable drug benefit because the medication is provider-administered. This is an advantage over Part D coverage because Part B has no coverage gap ("donut hole") and its cost-sharing structure is more predictable.

The standard Part B formula applies: after the annual deductible ($257 in 2026), Medicare pays 80% and the patient pays 20%. That 20% coinsurance on a $1,825 injection equals $365 per dose, or $4,380 over 12 months. A Medigap plan (such as Plan G or Plan N) can cover most or all of that coinsurance.

Colorado Medicare Advantage plans from Kaiser, UnitedHealthcare, Humana, and Aetna may have different cost-sharing structures. Some use fixed copays for Part B drugs rather than percentage-based coinsurance. Check your plan's Evidence of Coverage document or call the plan's specialty pharmacy line to confirm the exact patient cost before starting treatment.

The Medicare IRMAA surcharge does not directly affect Evenity cost, but higher-income beneficiaries already paying IRMAA should factor this into their total healthcare budget for the 12-month treatment window.